Schonfeld Strategic Advisors LLC Sells 92,518 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Schonfeld Strategic Advisors LLC decreased its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 12.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 670,600 shares of the company's stock after selling 92,518 shares during the period. Schonfeld Strategic Advisors LLC owned approximately 0.85% of Viridian Therapeutics worth $12,855,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of VRDN. R Squared Ltd bought a new stake in shares of Viridian Therapeutics during the 4th quarter valued at about $26,000. Foresite Capital Management VI LLC bought a new position in shares of Viridian Therapeutics during the 4th quarter worth approximately $38,000. AlphaQuest LLC grew its position in shares of Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after buying an additional 1,519 shares during the period. Summit Investment Advisors Inc. increased its stake in shares of Viridian Therapeutics by 24.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after acquiring an additional 1,516 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Viridian Therapeutics during the 4th quarter valued at $164,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on VRDN shares. Needham & Company LLC restated a "buy" rating and issued a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. HC Wainwright reaffirmed a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $35.70.

Viridian Therapeutics Stock Down 3.6 %

Viridian Therapeutics stock traded down $0.49 during trading on Monday, hitting $13.13. 355,524 shares of the company were exchanged, compared to its average volume of 1,195,354. The company has a market capitalization of $1.07 billion, a P/E ratio of -3.06 and a beta of 0.57. The business's 50 day moving average is $13.97 and its 200 day moving average is $17.85. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. Analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.